Jump to main content
eTG Complete
eTG Complete
Index
  1. Home
  2. Antibiotic
  3. Prevention of infection
  4. Primary prophylaxis in immunocompromised adults without HIV infection
  5. References
  6. Key references: Overview
  • Antibiotic
    • Bartonella infections
    • Osteomyelitis
    • Septic arthritis of a native joint
    • Bone and joint infections other than osteomyelitis and native joint septic arthritis
    • Sepsis or septic shock associated with a bone or joint source
    • Directed therapy for native bone or joint infection
    • Brucellosis
    • Infective endocarditis
    • Cardiovascular system infections other than endocarditis
    • Central nervous system infections
    • Coronavirus disease 2019 (COVID-19)
    • Cryptococcosis
    • Cytomegalovirus (CMV) infection
    • Infectious diarrhoea
    • Ear, nose and throat infections
    • Eye infections
    • Febrile neutropenia
    • Genital and sexually transmissible infections
    • Human immunodeficiency virus
    • Intra-abdominal infections
    • Leptospirosis
    • Lyme disease
    • Mediastinitis
    • Melioidosis
    • Mpox (monkeypox)
    • Nocardiosis
    • Nontuberculous mycobacterial infections
    • Oesophageal infections
    • Parasitic infections
    • Perinatal infections
    • Prevention of infection
      • Principles of surgical antibiotic prophylaxis
      • Surgical antibiotic prophylaxis for specific procedures
      • Prevention of infective endocarditis
      • Clearance antibiotics for invasive meningococcal or Hib disease
      • Prevention of infection in patients with asplenia or hyposplenism
      • Postexposure prophylaxis against bloodborne viruses
      • Prevention of infection in patients with cirrhosis and upper gastrointestinal bleeding
      • Primary prophylaxis in immunocompromised adults without HIV infection
        • What is covered in this topic?
        • Interventions to prevent opportunistic infections in immunocompromised patients
        • Assessing the need for antimicrobial prophylaxis in immunocompromised adults without HIV infection
        • Pneumocystis jirovecii pneumonia prophylaxis in immunocompromised adults without HIV infection
        • Toxoplasma gondii prophylaxis in immunocompromised adults without HIV infection
        • Cytomegalovirus prophylaxis in immunocompromised adults without HIV infection
        • Yeast and mould antifungal prophylaxis in immunocompromised adults without HIV infection
        • Herpes simplex virus and varicella-zoster virus prophylaxis in immunocompromised adults without HIV infection
        • Hepatitis B virus prophylaxis in immunocompromised adults without HIV infection
        • Mycobacterium tuberculosis prophylaxis in immunocompromised adults without HIV infection
        • Influenza virus prophylaxis in immunocompromised adults without HIV infection
        • Streptococcus pneumoniae prophylaxis in immunocompromised adults without HIV infection
        • Strongyloides stercoralis prophylaxis in immunocompromised adults without HIV infection
        • Burkholderia pseudomallei prophylaxis in immunocompromised adults without HIV infection
        • Neisseria meningitidis prophylaxis in adults treated with eculizumab
        • Progressive multifocal leukoencephalopathy (John Cunningham virus)
        • Further reading
        • References
          • Key references: Assessing the need for antimicrobial prophylaxis in immunocompromised adults without HIV infection
          • Key references: Overview
          • Key references: Patients taking corticosteroid therapy
          • Key references: Patients taking immunomodulatory drugs for nonmalignant conditions
          • Key references: Solid organ transplant patients
          • Key references: Haematopoietic stem cell transplant patients
          • Key references: Pneumocystis jirovecii pneumonia prophylaxis in immunocompromised adults without HIV infection
          • Key references: Toxoplasma gondii prophylaxis in immunocompromised adults without HIV infection
          • Key references: Cytomegalovirus prophylaxis in immunocompromised adults without HIV infection
          • Key references: Yeast and mould antifungal prophylaxis in immunocompromised adults without HIV infection
          • Key references: Herpes simplex virus and varicella-zoster virus prophylaxis in immunocompromised adults without HIV infection
          • Key references: Hepatitis B virus prophylaxis in immunocompromised adults without HIV infection
          • Key references: Mycobacterium tuberculosis prophylaxis in immunocompromised adults without HIV infection
          • Key references: Influenza virus prophylaxis in immunocompromised adults without HIV infection
          • Key references: Streptococcus pneumoniae prophylaxis in immunocompromised adults without HIV infection
          • Key references: Strongyloides stercoralis prophylaxis in immunocompromised adults without HIV infection
          • Key references: Burkholderia pseudomallei prophylaxis in immunocompromised adults without HIV infection
          • Key references: Neisseria meningitidis prophylaxis in adults treated with eculizumab
          • Key references: Progressive multifocal leukoencephalopathy (John Cunningham virus)
      • Prevention of invasive group A streptococcal infection
      • Prophylaxis for medicinal leech therapy
      • Selective decontamination of the digestive tract in patients on invasive mechanical ventilation
    • Q fever
    • Pneumonia
    • Directed therapy for pneumonia
    • Respiratory tract infections other than pneumonia
    • Acute rheumatic fever
    • Rickettsial infections
    • Salivary gland infections
    • Sepsis and septic shock: Identification and initial management
    • Sepsis and septic shock: Empirical regimens
    • Directed therapy for bloodstream infections, including sepsis and septic shock
    • Skin and soft tissue infections
    • Traumatic wound infections
    • Urinary tract infections in adults
    • Urinary tract infections in children
    • Identifying resistant pathogens or Candida species
    • Principles of obtaining blood for culture
    • Principles of antimicrobial use
    • Antimicrobial stewardship (AMS)
    • Practical information on using antimicrobial drugs
    • Aminoglycoside use
    • Vancomycin use in adults
    • Vancomycin use in young infants and children
    • Monitoring antimicrobial blood concentrations
    • Ambulatory antimicrobial therapy
    • Antimicrobial hypersensitivity
    • Kidney impairment and antimicrobial dosing
    • Contact details for health departments and public health units
    • Amikacin initial dose calculator
    • Gentamicin initial dose calculator
    • Tobramycin initial dose calculator

Key references: Overview

  • McCarthy MW, Walsh TJ. Checkpoint inhibitors and the risk of infection. Expert Review of Precision Medicine and Drug Development 2017;2(5):287–93. https://doi.org/10.1080/23808993.2017.1380517
  • Contact us
  • Conditions of use and disclaimer
  • Privacy policy
  • Copyright permission
  • Support and FAQ

www.tg.org.au
All site content © Therapeutic Guidelines Limited 2020. Therapeutic Guidelines Limited, Ground Floor, 473 Victoria Street, West Melbourne, Victoria 3003, Australia © Therapeutic Guidelines Ltd (eTG August 2020)

Created: No created attribute found. Modified: No revised attribute found. (HW Diagnostics)